Document is current
Any future updates will be listed below
-
Authors
Tiberi, Elisa
Parisi, Alessandro
Pistelli, Mirco
Savini, Agnese
Galassi, Federica
Reschini, Chiara
Quintavalle, Debora
Napoleoni, Riccardo
Ferrari, Carlo
Berardi, Rossana
- License Information
-
More Information
Article History
Received: 8 July 2024
Accepted: 29 April 2025
First Online: 26 May 2025
Declarations
:
: Alessandro Parisi received consultant/advisory board fees from AstraZeneca and Amgen and travel support from Merck, Daiichi-Sankio, and Accord. Elisa Tiberi received consultant/advisory board fees from Bayer and travel support from MSD and Merk. Agnese Savini received consultant/advisory board fees from AstraZeneca, Lilly, GSK, Gilead, Seagen, Genetic oncology, Roche, and Istituto Gentili. Mirco Pistelli received consultant/advisory board fees from AstraZeneca, Lilly, Gilead, Novartis, Pfizer, and Daiichi Sankyo and travel support from Roch and Msd. Federica Galassi, Chiara Reschini, Debora Quintavalle, Riccardo Napoleoni, and Carlo Ferrari declare no conflicts of interest. Rossana Berardi is an Editor-in-Chief of Oncology and Therapy. Rossana Berardi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
